Dilsher S. Dhoot

Ophthalmology
5404 W Cypress Ave
Ste 101
Visalia, CA 93277

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 37 publications

Early Versus Delayed Pegcetacoplan Treatment for Geographic Atrophy Secondary to Age-Related Macular Degeneration in OAKS, DERBY, and GALE.

Early Versus Delayed Pegcetacoplan Treatment for Geographic Atrophy Secondary to Age-Related Macular Degeneration in OAKS, DERBY, and GALE.

Journal: American journal of ophthalmology
Published: February 24, 2026

Efficacy of Continuous Pegcetacoplan Treatment for Subfoveal Geographic Atrophy in Age-Related Macular Degeneration: 36-Month Results from OAKS, DERBY, and GALE Open-Label Extension.

Efficacy of Continuous Pegcetacoplan Treatment for Subfoveal Geographic Atrophy in Age-Related Macular Degeneration: 36-Month Results from OAKS, DERBY, and GALE Open-Label Extension.

Journal: Clinical ophthalmology (Auckland, N.Z.)
Published: November 05, 2025

Effects of Time from Diagnosis to Treatment and Baseline Vision on Retinal Vein Occlusion Outcomes in Aflibercept 2 mg Phase III Trials.

Effects of Time from Diagnosis to Treatment and Baseline Vision on Retinal Vein Occlusion Outcomes in Aflibercept 2 mg Phase III Trials.

Journal: Ophthalmology. Retina
Published: November 04, 2025

Efficacy of Intravitreal Pegcetacoplan vs Avacincaptad Pegol in Patients With Geographic Atrophy.

Efficacy of Intravitreal Pegcetacoplan vs Avacincaptad Pegol in Patients With Geographic Atrophy.

Journal: Journal of vitreoretinal diseases
Published: October 20, 2025

Impact of Central Subfield Thickness Fluctuations on Visual Outcomes in Neovascular Age-Related Macular Degeneration in the VIEW Trials.

Impact of Central Subfield Thickness Fluctuations on Visual Outcomes in Neovascular Age-Related Macular Degeneration in the VIEW Trials.

Journal: Journal of vitreoretinal diseases
Published: August 25, 2025

Treatment of Retinal/Choroidal Vascular Diseases by Sustained Delivery of Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors.

Treatment of Retinal/Choroidal Vascular Diseases by Sustained Delivery of Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors.

Journal: American journal of ophthalmology
Published: April 15, 2025

Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE.

Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE.

Journal: American journal of ophthalmology
Published: December 20, 2024

Anatomic Control with Faricimab versus Aflibercept in the YOSEMITE/RHINE Trials in Diabetic Macular Edema.

Anatomic Control with Faricimab versus Aflibercept in the YOSEMITE/RHINE Trials in Diabetic Macular Edema.

Journal: Ophthalmology. Retina
Published: October 16, 2024

Longitudinal Changes in Diabetic Retinopathy Severity: Learnings from PANORAMA.

Longitudinal Changes in Diabetic Retinopathy Severity: Learnings from PANORAMA.

Journal: Ophthalmology. Retina
Published: June 12, 2024

Ocular and Systemic Risk Factors for Disease Worsening Among Patients with NPDR: Post Hoc Analysis of the PANORAMA Trial.

Ocular and Systemic Risk Factors for Disease Worsening Among Patients with NPDR: Post Hoc Analysis of the PANORAMA Trial.

Journal: Ophthalmology. Retina
Published: October 20, 2023

KESTREL and KITE Phase 3 Studies: 100-Week Results With Brolucizumab in Patients With Diabetic Macular Edema.

KESTREL and KITE Phase 3 Studies: 100-Week Results With Brolucizumab in Patients With Diabetic Macular Edema.

Journal: American journal of ophthalmology
Published: November 21, 2022

INCIDENCE OF NEW DIABETIC MACULAR EDEMA IN FELLOW EYES OF PATIENTS IN THE VISTA AND VIVID STUDIES.

INCIDENCE OF NEW DIABETIC MACULAR EDEMA IN FELLOW EYES OF PATIENTS IN THE VISTA AND VIVID STUDIES.

Journal: Retina (Philadelphia, Pa.)
Published: October 20, 2022
Showing 1-12 of 37

Last Updated: 09/26/2026